Evidence map›Paper›PMID 40837842›Full record

ArticlemicroLife2025

Luís Leónidas Cardoso, Marla Sofie Gaissmaier, Alexandra von Strempel, Tim Keys, Monica Steffi Matchado, Marta Salvado Silva, Diana Ring, Emma Slack, Bärbel Stecher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in microLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Genomic and functional characterization ofFrontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luís Leónidas CardosoMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.
Marla Sofie GaissmaierMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.
Alexandra von StrempelMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.
Tim KeysLaboratory for Mucosal Immunology, Institute of Food, Nutrition and Health, Department of Health Sciences and Technology, ETH Zürich, 8093 Zürich, Switzerland.ORCID https://orcid.org/0000-0003-2921-0362
Monica Steffi MatchadoMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.
Marta Salvado SilvaMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.
Diana RingMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.
Emma SlackLaboratory for Mucosal Immunology, Institute of Food, Nutrition and Health, Department of Health Sciences and Technology, ETH Zürich, 8093 Zürich, Switzerland.
Bärbel StecherMax von Pettenkofer-Institute for Hygiene and Clinical Microbiology, Ludwig-Maximilian University of Munich, 80336 Munich, Germany.ORCID https://orcid.org/0000-0002-7445-5193

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacteriophages are a promising tool for treating bacterial infections, given the rise and spread of antibiotic resistances. However, phage-resistant bacteria can emerge during treatment, jeopardizing the success of therapy

Indexed as

diarrheaESKAPEintestinal infectionmutationsphage efficacyPhage therapywithin host evolution

Identifiers

PMID40837842
PMCPMC12361893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.